

Language: English

Symposium fees:

AFPT - Club Phase 1 member fees
(2019 membership): **200 €**

Non-member fees: **300 €**

Academic student: **150 €**

Registration:

Required before: **Mars 15, 2019**

Registration form online on:

<https://www.linscription.com/activite.php?P1=15722>

Limited number of seats!

If you have any questions, please
email us at leclubphase1@gmail.com

Location :

Maison de la Chimie
28, rue Saint Dominique
75007 PARIS - France
Phone : (+33)1 40 62 27 00



Access :

RER: Line C, Invalides Station

Subway: Lines 8, 12 et 13, Assemblée
Nationale, Solférino or Invalides Stations

Bus: Lines 63, 69, 73, 83, 84 and 94



Suggested accommodations:

Saint Dominique Hotel
62, rue Saint Dominique

Best Western Tour Eiffel Invalides
35, boulevard de la Tour Maubourg

Hôtel de Varenne
44, rue de Bourgogne

Booking directly with the hotel

AFPT – Le Club Phase I (Association by law 1901)
is a founding member of 



with the support of



present

PBPK SYMPOSIUM 2019

PARIS - APRIL 4, 2019

ACT 3

*Physiologically Based
PharmacoKinetic modelling (PBPK):
A new Paradigm in Drug Development*



sponsored by **GENOPOLE**
VIVRE L'INNOVATION

PROGRAM

SESSION 1: Title to be defined

Chairs: name, name

- 8:30 AM Welcome coffee/tea
- 9:00 AM
- 9:00 AM **Food Effects**
Neil Parrott,
Modelling & Simulation Scientist,
Roche Innovation Center Basel
- 9:40 AM
- 9:40 AM **Developmental changes in drug disposition and responses: the challenges**
Jean-Marie Nicolas
UCB Biopharma
- 10:00 AM
- 10:00 AM **Break**
- 10:30 AM
- 10:30 AM **F.I.H 4 F.I.H: Faith in Holistic modelling for First-in-Human PK**
Neil Miller,
DMPK Investigator-PBPK Leader,
GSK
- 11:40 AM
- 11:40 AM **Physiological Based Absorption Modelling in industrial practice. Current applications and a vision for the future**
Xavier Pepin,
Principal Scientist,
Astrazeneca
- 12:00 PM
- 12:00 PM **Questions & Answers**
- 12:05 PM

SESSION 2: Early discovery (ADMET-PBPK), UGT metabolism

Chairs: name, name

- 12:05 PM
- 12:05 PM **Age-dependent variations in activity of hepatic UGT enzymes: Application to PBPK modelling**
Justine Badee,
Post-doctoral Associate,
Roche/University of Florida
- 12:45 PM
- 12:45 PM **Lunch**
- 2:00 PM
- 2:00 PM **Challenges of transporter IVIVE: a digoxin example**
Maelys De Sousa Mendes,
PhD, Research Scientist,
Simcyp
- 2:40 PM
- 2:40 PM **Discovery PBPK: Efficiently using machine learning & PBPK modeling to drive lead selection & optimization**
John DiBella,
President of Lancaster Division,
Simulations Plus
- 3:00 PM
- 3:00 PM **Questions & Answers**
- 3:05 PM

AFPT – Le Club Phase I (Association by law 1901)
is a founding member of 

SESSION 3: PBPK in special populations: Pediatric and pregnancy models

Chairs: name, name

- 3:05 PM
- 3:05 PM **Analysis of UGT activity changes during pregnancy through PBPK modeling**
Andre Dallmann,
Scientist Systems Pharmacology,
Bayer
- 3:45 PM
- 3:45 PM **Paediatric and Pregnancy PBPK/PD Modelling: Clinical and Drug Development Applications**
Trevor Johnson,
Principal Scientist,
Simcyp
- 4:25 PM
- 4:25 PM **Break**
- 4:45 PM
- 4:45 PM **SESSION 4:
What's new for regulatory requirements?**
- 4:45 PM
- 4:45 PM **The finalised EMA guideline and latest experience of PBPK models in Regulatory submissions**
Susan Cole,
Expert Pharmacokinetics Assessor,
MHRA
- 5:25 PM
- 5:25 PM **Questions & Answers**
- 5:30 PM
- 5:30 PM **Closing Remarks**
- 6:00 PM